Newsroom Archives - Page 14 of 23 - Spectral Medical Inc

Spectral Medical Provides Update on Tigris Clinical Trial

Provides positive case study on patient enrolled at University of Michigan 14 clinical sites actively enrolling patients with 40 patients now randomized TORONTO, Canada – July 20, 2022 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage...

Spectral Medical Highlights From Vicenza Course 2022

Video replay of sponsored symposium explaining endotoxemic septic shock and the case for hemoperfusion therapy TORONTO, Canada – July 14, 2022 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic...

Spectral Medical to Participate at the Benzinga All Access event on July 15, 2022

TORONTO, Canada – July 13, 2022 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal...

US FDA Grants Spectral Medical Breakthrough Device Designation for Toraymyxin™ (“PMX”) for the Treatment of Endotoxemic Septic Shock

Breakthrough designation expected to help accelerate regulatory review TORONTO, Canada – July 11, 2022 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today...

Spectral Medical Inc. Announces Results of Annual and Special Meeting of Shareholders

TORONTO, June 21, 2022 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting...

Spectral and Dialco Announce Dr. John Kellum to be Featured as Keynote Lecturer at the 40th Vicenza Course on AKI and CRRT 2022

Dr. Kellum Invited to Participate on Additional Featured Panels TORONTO, Canada – June 14, 2022 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as...

« Older Entries

Next Entries »

EAA™ and PMX are licensed and available for use in Canada. PMX is not approved for clinical use in the USA, and is currently undergoing the PMA (Premarket approval) process. EAA™ is FDA cleared for use in the USA. The information presented herein is region specific. Please contact Spectral Medical Inc.to obtain appropriate product information for your country.